 |
|
Study identifies biomarker that safely monitors tumor response to new brain cancer treatment
July 01, 2009A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma mulitforme. The finding, reported in the July 1 issue of Clinical Cancer Research, paves the way for a Phase 1 clinical trial expected to begin in late 2009.
The gene therapy is a two-pronged strategy devised by scientists at the Cedars-Sinai Board of Governors Gene Therapeutics Research Institute. It uses a genetically engineered, harmless virus to deliver a combination of proteins and a drug to kill tumor cells, which triggers an ongoing immune response against malignant brain tumors cells.
The Cedars-Sinai team led by Pedro R. Lowenstein, M.D., Ph.D., director of the Board of Governors Gene Therapeutics Research Institute, and Maria G. Castro, Ph.D., co-director of the Institute, developed this gene therapy strategy during 10 years of laboratory research.
"Using this therapy, we have shrunk and completely eliminated very large brain tumors in animals and have trained their immune systems to develop memory so that recurrent tumors are also destroyed," said Castro, principal investigator of the study. "The biomarker identified in this study will help us determine the effectiveness of the therapy in patients with glioblastoma multiforme."
In this study, the researchers identified the most effective and least toxic combination of therapeutic agents that would offer the best results. They found that a protein released by dying tumor cells may be used as a "biomarker" to gauge the effectiveness of treatment. This protein, called "high mobility group box 1" (HMGB1), regulates gene expression in healthy cells by binding to the cells' DNA. When cancerous cells are killed, however, HMGB1 is released into the general blood circulation. This research shows that measuring the levels of HMGB1 in the blood could be a non-invasive but essential way to monitor the effectiveness of cancer therapeutics in patients. These findings will be used to fine-tune the therapy as it enters the Phase I clinical trial.
Traditional treatments have little impact on long-term survival of patients with glioblastoma multiforme, the most common malignancy in the brain, diagnosed in about 18,000 people in the United States every year.
The immune system is considered a potential ally, but the brain has few dendritic cells -- key sentries of the immune system that detect foreign proteins and provide the very initial signals for the T cells to mount an anti-tumor immune attack. Without the surveillance of dendritic cells, brain tumors go undetected and proliferate rapidly.
In the technique devised by Castro and Lowenstein, one of the proteins (the immune stimulatory cytokine Flt3L) attracts dendritic cells from bone marrow into the tumor while another protein (thymidine kinase) and the antiviral drug gancyclovir combine to kill tumor cells. The dying tumor cells are detected by the newly recruited dendritic cells, which initiate the anti-tumor response. The biomarker identified in this study is a result of the ongoing battle between the T cells and the tumor cells. As such, the biomarker will be a useful direct reporter of the ensuing fight to kill the tumor.
Cedars-Sinai Medical Center
"Using this therapy, we have shrunk and completely eliminated very large brain tumors in animals and have trained their immune systems to develop memory so that recurrent tumors are also destroyed," said Castro, principal investigator of the study. "The biomarker identified in this study will help us determine the effectiveness of the therapy in patients with glioblastoma multiforme."
In this study, the researchers identified the most effective and least toxic combination of therapeutic agents that would offer the best results. They found that a protein released by dying tumor cells may be used as a "biomarker" to gauge the effectiveness of treatment. This protein, called "high mobility group box 1" (HMGB1), regulates gene expression in healthy cells by binding to the cells' DNA. When cancerous cells are killed, however, HMGB1 is released into the general blood circulation. This research shows that measuring the levels of HMGB1 in the blood could be a non-invasive but essential way to monitor the effectiveness of cancer therapeutics in patients. These findings will be used to fine-tune the therapy as it enters the Phase I clinical trial.
Traditional treatments have little impact on long-term survival of patients with glioblastoma multiforme, the most common malignancy in the brain, diagnosed in about 18,000 people in the United States every year.
The immune system is considered a potential ally, but the brain has few dendritic cells -- key sentries of the immune system that detect foreign proteins and provide the very initial signals for the T cells to mount an anti-tumor immune attack. Without the surveillance of dendritic cells, brain tumors go undetected and proliferate rapidly.
In the technique devised by Castro and Lowenstein, one of the proteins (the immune stimulatory cytokine Flt3L) attracts dendritic cells from bone marrow into the tumor while another protein (thymidine kinase) and the antiviral drug gancyclovir combine to kill tumor cells. The dying tumor cells are detected by the newly recruited dendritic cells, which initiate the anti-tumor response. The biomarker identified in this study is a result of the ongoing battle between the T cells and the tumor cells. As such, the biomarker will be a useful direct reporter of the ensuing fight to kill the tumor.
Cedars-Sinai Medical Center
Tumor Cells Current Events and Tumor Cells News RSSCancers' Sweet Tooth May Be Weakness
The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.
UCLA researchers create 'fly paper' to capture circulating cancer cells
Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.
'Cross-talk' mechanism contributes to colorectal cancer
Researchers at the University of Wisconsin-Madison School of Medicine and Public Health have identified a molecular mechanism that allows two powerful signaling pathways to interact and begin a process leading to colorectal tumors.
CSHL study shows that some malignant tumors can be shut down after all
Oncologists have had their hands tied because more than half of all human cancers have mutations that disable a protein called p53.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
New Notre Dame study provides insights into the molecular basis of tumor cell behavior
A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression.
Immune therapy can protect against or treat later lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection.
Study reveals a 'missing link' in immune response to disease
The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.
Discovery offers potential new pancreatic cancer treatment
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
A Potential Anti-cancer Agent
Pateamine A (PatA), a natural product first isolated from marine sponges, has attracted considerable attention as a potential anti-cancer agent, and now a new activity has been found for it, which may reveal yet another anti-cancer mechanism.
More Tumor Cells Current Events and Tumor Cells News Articles
 |
Cancer Cell Culture: Methods and Protocols (Methods in Molecular Medicine) by Simon P. Langdon (Editor) Western General Hospital, Edinburgh, UK. Describes easy-to-follow methods for guiding researchers on new techniques in cell and molecular biology of cancer, Features the basic concept of cancer cell culture and general techniques used in many cell culture facilities. Also covers the isolation of specific cancer cell types. For researchers. |
 |
Cure Ovarian Germ Cell Tumor Long Sleeve T-shirt Large White by Shop Zeus |
 |
Fight Against Germ Cell Tumor Keychain by Design a Product LLC Text on keychain: Fight Against Germ Cell Tumor * Durable acrylic key chain is crystal-clear and double-sided so the artwork or message is seen twice. * Sturdy metal ring holds your keys securely. * Full color printed images or messages are included. * If you have new ideas or need help selecting text for your custom keychains please contact us. * Size: 2 1/8" x 3 1/2" (Approx. business card) |
 |
Mobile Starring: Keith Allen, Julie Graham, Michael Kitchen, Samantha Bond, Jamie Draven Directed By: Stuart Orme Conspiracy, betrayal, and revenge in the global telecom industry Someone is blowing up mobile-phone towers across England. Messages scrawled in blood-red paint at the scenes proclaim that mobile phones are the instruments of the devil. What’s more, a gunman -- or gunmen -- is shooting cell phone users in mid-conversation. Baffled police investigators scramble to avert public panic. In four interlocking parts, this tense drama peels back the layers of a terrorist conspiracy, gradually revealing the evil at its core. We follow three characters -- a disgraced telecom executive (Michael Kitchen, Foyle’s War), a bitter ex-soldier (Jamie Draven, Billy Elliot), and a disgruntled engineer (Neil Fitzmaurice, Going Off Big Time) -- all united by circumstance or collusion. In a style... |
 |
Maximum Intenational Maximize Graviola 750, 750mg Graviola, 100 Veggie Caps by Maximum International Having attracted worldwide interest as an inhibitor of malignant cell growth, this remarkable Amazonian herb has been studied in more than 20 laboratory tests for its anti-tumor and cell protective qualities. The best Graviola on the market. Maximum Int'l. is the company with the most potent products available. Lab tested to make sure the ingredients are of the most superior quality and highes quality raw materials available. This product is manufactured in an FDA inspected and GMP certified facility. Quality is guaranteed. |
 |
Germ Cell Tumors (ACS ATLAS OF CLINICAL ONCOLOGY) by Derek Raghavan (Author) Crafted as a descriptive and visual text, Germ Cell Tumors features definitive reviews of the biology, diagnosis, and management of germ cell tumors. Incorporating extensive illustrations and tables, this book reviews the progress that has been made in the curative therapy of germ cell tumors over the past 25 years, progress that has lead to the positioning of germ cell tumor therapy as the paradigm of curative treatment in adult solid tumors. Most of the work has been produced on a multidisciplinary basis, emphasizing the use of different diagnostic, laboratory, imaging, and management tools. In addition to a scientific and clinical review, this book features a series of detailed discussions on the psychosocial issues, patient support, and management of the occasional problem cases that... |
 |
Atlas of Human Tumor Cell Lines by Robert K.M. Hay (Editor), Jae-Gahb Park (Editor), Adi Gazdar (Editor) Human tumor cells in culture are valuable for studying cancer causes and properties. This convenient reference provides useful information for cancer researchers on commonly used, established tumor cell lines of the major human organ systems. Atlas of Human Tumor Cell Lines includes data about morphological, metabolic, genetic, and growth characteristics of human tumor cells, with morphological characteristics presented in more than 250 photomicrographs. It also contains information for establishing and maintaining human tumor cell lines in culture, and each chapter covers future perspectives. * * Covers well-characterized tumor cell lines from the major human organ systems * Presents over 250 photomicrographs, both phase-contrast... |
 |
Fight Against Extracranial Germ Cell Tumor Long Sleeve T-shirt Large White by Shop Zeus |
 |
Organic Noni Juice, Morinda Citrifolia, Unflavored, Vegetarian 16 oz by Dynamic Health Laboratories by Dynamic Health It is believed that the Noni (Morinda Citrifolia) tree originated in Southeast Asia about two thousand years ago. Since that time, the precious fruit of the Noni tree has been distributed throughout the islands of the South Pacific, as the tree will only thrive in the delicate ecosystem of the tropics. The great gifts of the Noni fruit are well-known in tropical cultures. Noni Juice (Morinda Citrifolia) has traditionally been used to cleanse and purify the entire system, as a defense against illness, to aid digestion, to heal abrasions, to reduce swelling and inflammation and reduce pain. Dynamic Health Laboratories, Inc. offers a variety of Noni formulas so that you can choose the one that's right for you. Usage: Take 2 tablespoons (1fl.oz) daily on an empty stomach, preferably in the... |
 |
Cancer Stem Cells: Novel Concepts and Prospects for Tumor Therapy (Ernst Schering Foundation Symposium Proceedings) by O.D. Wiestler (Editor), B. Haendler (Editor), D. Mumberg (Editor) Cancer stem cells have originally been identified in leukemia and later in several solid tumor types. They have very different properties from the bulk of the tumor, as they divide much more slowly and have very efficient drug- resistance mechanisms. Current treatments might largely spare cancer stem cells, thus leading to tumor recurrence and metastasis. The recent identification of growth and differentiation pathways responsible for cancer stem cell proliferation and survival will help in the discovery identification of novel therapeutic targets. Developing selective drugs against cancer stem cells offers great therapeutic opportunities but also provides for major challenges regarding preclinical models, therapeutic windows, and clinical study end points. |
| © 2009 BrightSurf.com |